DexCom, Inc.’s Stock Price Soars to $140.10, Marks a Robust 5.20% Increase

DexCom, Inc. (DXCM)

140.10 USD +6.92 (+5.20%) Volume: 3.92M

Boosted by a trading session increase of +5.20%, DexCom, Inc.’s stock price is currently performing strongly at 140.10 USD, with a trading volume of 3.92M. An impressive year-to-date percentage change of +12.90% further solidifies DXCM as a noteworthy player in the stock market.

Latest developments on DexCom, Inc.

DexCom Inc. (NASDAQ:DXCM) has been on a surprising 14% stock rally, outperforming competitors on a strong trading day and reaching a new 52-week high at $140.88. With a 26% ROE, better than average, and a 3.48% rise in a week, investors are taking notice. New investments from CX Institutional and Oak Harvest Investment Services, along with a maintained ‘Buy’ rating from Citi, are contributing to the positive stock price movements. However, a mixed verdict on CGM tech patent infringement adds a note of caution.

DexCom, Inc. on Smartkarma

Dexcom Inc, a medical device company that focuses on designing, developing, and delivering innovative products, has been receiving positive analyst coverage on Smartkarma, an independent investment research network. According to Baptista Research, a top independent analyst on the platform, Dexcom Inc has shown solid market penetration in the basal and hypo non-insulin markets. The company’s growth has been bolstered by its international expansion efforts, which are expected to drive future growth. With a bullish sentiment, Baptista Research believes that Dexcom Inc‘s notable accomplishments, including a 24% growth in total revenue, have positioned the company for success. This was reported during the company’s Fourth quarter and Fiscal year 2023 earnings call, which highlighted over $700 million in organic revenue growth compared to the previous year.

A look at DexCom, Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

According to Smartkarma Smart Scores, the long-term outlook for Dexcom Inc is looking positive. The company has received a score of 2 for value, indicating that it may be undervalued in the market. However, it has only received a score of 1 for dividend, meaning that it may not be a good choice for investors looking for regular income.

On the other hand, Dexcom Inc has received a score of 3 for both growth and resilience. This suggests that the company is expected to experience steady growth in the future and is well-equipped to handle any potential challenges. Additionally, the company has received a high score of 4 for momentum, indicating that it is currently performing well in the market.

Dexcom Inc is a medical device company that specializes in continuous glucose monitoring systems for people with diabetes. Their innovative technology includes an implantable device that measures glucose levels under the skin and an external receiver that displays this information. With a positive outlook based on the Smartkarma Smart Scores, Dexcom Inc may be a promising investment for those looking for long-term growth potential.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma